EBIT SEK 40m vs. ABG SEK 47m; Q4e likely weaker Pulp moving into more challenging territory – prices...
The weakness of Etteplan’s Q3 came as a no surprise as the company released two profit warnings befo...
Raute’s EUR 46.4m Q3 revenue was soft relative to our estimate, yet the EUR 6.
Exel’s Q3 revenue continued to grow y/y, albeit not quite as fast as was estimated since the figures...
ODI Pharma announced on October 30th that the company has resolved to carry out a rights issue of ap...
Konjunkturen är svag och volymerna minskar men kontraktstillverkaren AGES Industri tar nya marknadsa...
Sales +1% vs cons, adj. EBITA +1% vs cons Cons. EBITA estimate revisions slightly positive Improved ...
Redeye provides a short comment on Ortoma’s Q3 report this morning.
Q3 Sales and Profits beat estimates, but the economic downturn affects demand.
Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.
Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution to...
Redeye is making some downward revisions to our near-term forecasts on the back of softer Q3 numbers...
Redeye comments on Leqembi’s Q3 sales, disclosed earlier today in connection with Biogen’s quarterly...
Redeye retains its positive view of Vertiseit following a solid Q3 matching our expectations.
Redeye provides a brief comment on Verve Group’s Q3 organic growth figure of 31%, up from 26% in Q2 ...
